

## Instructions to Contributors

Dear Contributor:

Enclosed in this document please find the page proofs, copyright transfer agreement (CTA), and offprint order form for your article in the *Seminars in Neurology*, Volume 33, Number 4, 2013. Please print this document and complete and return the CTA and offprint order form, along with corrected proofs, within 72 hours.

- 1) Please read proofs carefully for **typographical** and **factual** errors only; mark corrections in the margins of the proofs in blue or black pen; please be sure to write as clearly as possible so no errors are introduced into your article. **Answer (on the proofs) all author queries marked in the margins of the proofs.** Check references for accuracy. **Please check on the bottom of the 1st page of your article that your titles and affiliations are correct.** Avoid elective changes, because these are costly and time consuming and will be made at the publisher's discretion.
- 2) Please pay particular attention to the proper placement of figures, tables, and legends. Please provide copies of any formal letters of permission that you have obtained.
- 3) **Please return the corrected proofs, signed copyright transfer agreement, and your offprint order form.**
- 4) As a contributor to this journal you will receive a complimentary PDF file of the article after publication.
  - If you wish to order offprints, **please circle the quantity required** (left column) **and the number of pages in your article.** If you wish to order copies of the journal please enter the number of copies on the indicated line.
  - If you do not want to order offprints or journals simply put a slash through the form, **but please return the form.**

**Please return all materials within 72 hours. E-mail is the easiest way to ensure your corrections are received in a timely manner. You may also return materials via fax or overnight mail to:**

Teresa Exley, Production Editor  
Absolute Service, Inc.  
8600 LaSalle Road, The Oxford Building,  
Suite 602  
Towson, Maryland 21286  
Phone: 410-830-6022  
Fax: 410-830-4099  
Email: [teresa.exley@absoluteserv.com](mailto:teresa.exley@absoluteserv.com)

Please do not return your materials to the editor or the typesetter.

**Please note:** Due to a tight schedule, if the publisher does not receive the return of your article proofs within 7 days of the date the e-mail was sent to you, the publisher reserves the right to proceed with publication without author changes. Such proofs will be proofread by the editor and the publisher.

Thank you for your contribution to this journal.

Thieme Medical Publishers, Inc. (the "Publisher") will be pleased to publish your article (the "Work") entitled \_\_\_\_\_ in the *Seminars in Neurology*, Volume 33, Number 4, 2013.

The undersigned Author(s) hereby assigns to the Publisher all rights to the Work of any kind, including those rights protected by the United States Copyright laws.

The Author(s) will be given permission by the Publisher, upon written request, to use all or part of the Work for scholarly or academic purposes, provided lawful copyright notice is given.

If the Work, subsequent to publication, cannot be reproduced and delivered to the Author(s) by the publisher within 60 days of a written request, the Author(s) is given permission to reprint the Work without further request.

The Publisher may grant third parties permission to reproduce all or part of the Work. The Author(s) will be notified as a matter of courtesy, not as a matter of contract. Lawful notice of copyright always will be given.

Check appropriate box below and affix signature.

I Sign for and accept responsibility for transferring copyright of this article to Thieme Medical Publishers, Inc. on behalf of any and all authors.

**Author's full name, degrees, professional title, affiliation, and complete address:**

\_\_\_\_\_  
Author's printed name, degrees

\_\_\_\_\_  
Professional title

\_\_\_\_\_  
\_\_\_\_\_

\_\_\_\_\_  
Complete professional address

\_\_\_\_\_  
Author's signature

\_\_\_\_\_  
Date

I prepared this article as part of my official duties as an employee of the United States Federal Government. Therefore, I am unable to transfer rights to Thieme Medical Publishers, Inc.

\_\_\_\_\_  
Author's signature

\_\_\_\_\_  
Date

Order Form for Offprints and additional copies of the Seminars in Neurology  
(Effective January 2013)

**Please circle the cost of the quantity/page count you require (orders must be in increments of 100)**

Quantity	Pages in Article / Cost				
	1 to 4	5 to 8	9 to 12	13 to 16	17 to 20
<b>100</b>	\$298	\$497	\$746	\$968	\$1,158
<b>200</b>	\$397	\$646	\$970	\$1,258	\$1,495
<b>300</b>	\$496	\$798	\$1,198	\$1,568	\$1,869
<b>400</b>	\$549	\$886	\$1,330	\$1,735	\$2,075
<b>500</b>	\$598	\$966	\$1,450	\$1,886	\$2,262
<b>1000</b>	\$1,076	\$1,739	\$2,610	\$3,385	\$3,995

Volume/Issue #: \_\_\_\_\_ Page Range (of your article): \_\_\_\_\_

Article Title: \_\_\_\_\_

MC/Visa/AmEx No: \_\_\_\_\_ Exp. Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Address: \_\_\_\_\_

City/State/Zip/Country: \_\_\_\_\_

Corresponding author will receive a complimentary PDF of the article after publication.

Number of **additional** copies of the journal, at the discounted rate of \$25.00 each: \_\_\_\_\_

**Notes**

1. The above costs are valid only for orders received before publication of the issue. **Reprints ordered after printing will be substantially more expensive.**

2. **A shipping charge will be added to the above costs.**

3. Reprints are printed on the same coated paper as the journal and saddle-stitched.

4. For larger quantities or late orders, please contact reprints department: Phone: +1(212) 584-4662  
Fax: +1(212) 947-1112  
E-mail: [reprints@thieme.com](mailto:reprints@thieme.com)

# The Genetics of Dementia

Janice L. Farlow<sup>1Q1</sup> Tatiana Foroud, PhD<sup>1</sup>

Q1

<sup>1</sup> Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana

**Address for correspondence** Tatiana Foroud, PhD, Department of Medical and Molecular Genetics, Indiana University School of Medicine, 410 West 10th Street (HS 4021), Indianapolis, IN 46202 (e-mail: tforoud@iu.edu).

Semin Neurol 2013;33:417–422.

## Abstract

Over the past decade, there has been a dramatic evolution of genetic methodologies that can be used to identify genes contributing to disease. Initially, the focus was primarily on classical linkage analysis; more recently, genomewide association studies, and high-throughput whole genome and whole exome sequencing have provided efficient approaches to detect common and rare variation contributing to disease risk. Application of these methodologies to dementias has led to the nomination of dozens of causative and susceptibility genes, solidifying the recognition that genetic factors are important contributors to the disease processes. In this review, the authors focus on current knowledge of the genetics of Alzheimer's disease and frontotemporal lobar degeneration. A working understanding of the genes relevant to common dementias will become increasingly critical, as options for genetic testing and eventually gene-specific therapeutics are developed.

## Keywords

- ▶ genetic risk factors
- ▶ dementia
- ▶ Alzheimer's disease
- ▶ frontotemporal lobar degeneration

## Overview of Modern Genetic Technologies

The past few decades have seen exponential advances in the ability to identify genes contributing to disease. Beginning with the identification of microsatellite markers and then single nucleotide polymorphisms (SNPs) in the early 1990s, researchers were able to interrogate<sup>Q2</sup> the genome to detect genes causing Mendelian disorders. Linkage analysis was the most common use of these markers and sought to identify chromosomal regions shared by affected members within a family. It was hypothesized that a gene that caused the disease lay within these shared chromosomal regions. The result of linkage analysis was a rapid identification of the genetic cause for many Mendelian disorders. This in turn has provided key insights into disease pathogenesis and in some cases has led to novel therapeutics.

Over the past decade, advancing genetic technologies have allowed millions of SNPs to be efficiently interrogated using genotyping arrays. These arrays include primarily common variation and have allowed scientists to explore new hypotheses about the role of genetics in human disease. For example, studies can now be designed to identify genetic factors that increase or decrease the risk of disease. The most common approach that has been used is a genomewide association study (GWAS), which compares a sample of cases with

disease to controls who do not have the disease. Because many genetic risk factors have modest individual effect on disease risk, large samples of cases and controls are needed to obtain robust, reproducible associations. More recently, meta-analysis has been widely used to combine results from multiple studies. This has resulted in studies using data from thousands of cases and controls to identify SNPs that are associated with disease risk. A GWAS is based on the premise of linkage disequilibrium, meaning that many SNPs are tested and used as proxies for the entire genome. Thus, analyses can determine that a SNP is *associated* with disease risk, but cannot confirm that this particular SNP *functionally contributes* to disease risk.

In the past few years, technology has further advanced to allow sequencing of DNA to be cost effective on a large scale. Rather than limiting sequencing to a gene or a small region of a chromosome, it is now possible to sequence the entire genome (whole genome sequencing) or only the gene-coding regions, the gene exons (whole exome sequencing). The ability to perform such extensive DNA sequencing has allowed researchers to examine the role of rare variation in disease. For example, whole exome sequencing within a family or across many families can be used to identify genes in which rare variants are found at greater frequency among the affected individuals as compared with control subjects

Q2

**Issue Theme** Neurodegenerative Dementias; Guest Editor, Brandy R. Matthews, MD

Copyright © 2013 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.  
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0033-1359313>.  
ISSN 0271-8235.

who do not have the disease. Whole exome sequencing is often focused on the identification of rare, functional variants, which may alter the structure or function of the resulting protein. The types of variants that can be identified with this method are not limited to single nucleotide variants, but can also include small insertions and deletions.

Whole exome and whole genome sequencing presents a challenge to researchers due to the large number of sequence variants that are identified (~40,000 per exome and 3 million per genome). Large numbers of subjects are required to identify candidate genes in complex diseases like Alzheimer's disease (AD), and the cost is often prohibitive. New bioinformatics technologies are constantly in development for analysis of sequencing experiments, but further effort will be required to validate, compare, and combine these tools. Almost all of these genetic tools and technologies have been used to study dementia. This review will describe what has been learned about the genetics of specific types of dementia, Alzheimer's disease, and frontotemporal lobar degeneration (FTLD).

## The Genetics of Alzheimer's Disease

Alzheimer's disease is the most common neurodegenerative disorder among the elderly, as well as the most common cause of dementia overall. The key neuropathologic findings in AD are amyloid plaques composed of  $\beta$ -amyloid ( $A\beta$ ) and neurofibrillary tangles consisting of the tau protein. Alzheimer's disease is likely caused by a combination of genetic and environmental factors. Alzheimer's disease is typically categorized into early onset (EOAD; onset < 60 years) and late-onset (onset  $\geq$  60 years). Early-onset Alzheimer's disease makes up less than 5% of cases, but because a subset of families has a clear pattern of Mendelian inheritance, mutations have been identified in several causative genes. The identification of these genes has significantly advanced the understanding of the biological underpinnings of all AD cases.

### Early-Onset Alzheimer's Disease

Researchers observed that among families with EOAD, a significant number displayed autosomal dominant inheritance. This allowed linkage analysis to be successfully employed to identify three causative genes (*APP*, *PSEN1*, and *PSEN2*).

*APP* was the first EOAD gene to be identified.<sup>1,2</sup> It is located on chromosome 21 and encodes the  $\beta$ -amyloid precursor protein. The  $\beta$ -amyloid precursor protein is a neuronal protein that is sequentially cleaved by two specific proteases ( $\beta$ -secretase and  $\gamma$ -secretase) to release  $A\beta$ . Even before *APP* was identified, biochemical analysis had identified cerebral  $A\beta$  deposits in the brains of patients with AD. In addition, it had been found that patients with Down's syndrome were more likely to develop AD; therefore, it was predicted that a gene on chromosome 21 would function to produce  $A\beta$  and would cause AD when mutated.<sup>3</sup>

Mutations in *APP* are found in less than a quarter of EOAD patients. A variety of different mutations have been found in *APP* including point mutations, gene duplications, and gene


deletions. All *APP* mutations reported to be pathogenic are located at secretase sites or inside the sequence for the resulting  $A\beta$  peptide, in or near exons 16 and 17 (►Fig. 1).<sup>4</sup>

The majority of EOAD mutations are found in the presenilin 1 (*PSEN1*) gene, located on chromosome 14 and discovered a few years after *APP*.<sup>5</sup> There have been 185 different mutations found in this gene alone, most clustering in the transmembrane portion of the protein. Sequence homology with *PSEN1* prompted the relatively rapid identification of the presenilin 2 (*PSEN2*) gene on chromosome 1.<sup>6,7</sup> Mutations in this gene are quite rare and were initially due to a founder mutation among individuals of Volga-German ancestry. Mutations in *PSEN2* have now been found in individuals of other ancestry as well.<sup>8-10</sup> Of those that have been reported as pathogenic mutations, the distribution within resultant protein domains is similar to that of *PSEN1*. Together, presenilin 1 (*PSEN1*) and presenilin 2 (*PSEN2*) serve as critical catalytic components of the  $\gamma$ -secretase.<sup>11</sup>

Over 200 different mutations have been identified in these three EOAD genes, and most are fully penetrant (►Table 1; consult the Alzheimer Disease and Frontotemporal Dementia Mutation database, <http://www.molegen.ua.ac.be/ADMutations>, for updated information).<sup>12</sup> Disease-causing mutations in these three genes all lead to an increase in extracellular  $A\beta$  or a relative overabundance of the  $A\beta_{42}$  species, which is thought to increase  $A\beta$  aggregation and amyloid fibril formation.<sup>13</sup> The discovery of *APP*, *PSEN1*, and *PSEN2* contributed to the amyloid hypothesis, which posits that amyloid plays a critical role in AD pathology.

### Late-Onset Alzheimer Disease

Although most LOAD cases do not have a clear heritable etiology, genetic factors still play an important role in disease risk. The lifetime risk of developing AD is ~10%, and is twice that for individuals having an affected first-degree relative with AD.<sup>14</sup> Studies have estimated that the genetic



**Fig. 1** Location of mutations within the *APP* protein product as generated from the Alzheimer Disease and Frontotemporal Dementia Mutation database.<sup>12</sup> Depicted is the chain of amino acids produced from the *APP* gene. Green indicates sites of reported nonpathogenic mutations, and red indicates sites of reported pathogenic mutations. Sites of cleavage by secretases are shown in blue.

**Table 1** Mendelian genes causing familial early-onset Alzheimer's disease (EOAD)

Gene	Protein	Chromosome location	Mutation frequency in EOAD patients <sup>a</sup>	Types of mutations reported
<i>APP</i>	B-amyloid precursor protein	21q21.2	6–26%	Missense, duplications, deletions
<i>PSEN1</i>	Presenilin 1	14q24.3	28–61%	Missense, deletions, insertions
<i>PSEN2</i>	Presenilin 2	1q31–42	Rare	Missense

<sup>a</sup>Mutation frequencies reported by Cohn-Hokke et al.<sup>31</sup>

contribution to LOAD susceptibility (i.e., heritability) is as high as 80%.<sup>15</sup> Of note, no single gene has been identified that has a causative effect on disease risk in LOAD, which would be analogous to the role of *APP*, *PSEN1*, or *PSEN2* in EOAD.

The apolipoprotein E gene (*APOE*) was the first gene discovered as a risk factor for LOAD, and it remains the identified locus that confers the greatest susceptibility to the disease. *APOE* is a well-known gene involved in lipid metabolism, and it is thought to be important in A $\beta$  clearance, as well. There are three isoforms of *APOE* ( $\epsilon$ 2,  $\epsilon$ 3,  $\epsilon$ 4) that differ by a single amino acid substitution. It has been shown that this minor difference leads to different levels of clearance of A $\beta$ , with the  $\epsilon$ 4 allele of *APOE* (*APOE4*) significantly decreasing the speed of clearance at the blood–brain barrier.<sup>16</sup>

The  $\epsilon$ 4 allele of *APOE* (*APOE4*) increases the risk of AD with reported odds ratios ranging from 4 to 15.<sup>17</sup> The effect of *APOE4* is consistently present across populations and ethnicities.<sup>18–20</sup> The *APOE4* effect is additive, with those having two *APOE4* alleles having a 15-fold greater risk of AD as compared with the 4-times increased risk for those carrying a single copy of the risk allele.<sup>21</sup> Meanwhile, the  $\epsilon$ 2 allele (*APOE2*) decreases the risk of AD by approximately a quarter, and is considered a protective allele.<sup>21</sup> The  $\epsilon$ 3 allele of *APOE* (*APOE3*), the most common of the 3 *APOE* isoforms, has not been shown to have a detrimental or protective effect. Importantly, the *APOE2* and *APOE4* alleles modify the risk of AD, but neither is causative (i.e., sufficient to cause or protect against AD alone).

Other than *APOE*, almost 50 additional genetic risk factors have now been linked to AD. Varying levels of support exist for each gene. Nine genes have been labeled as established risk factors for AD, based on genome-wide significance ( $p$  value  $\leq 5 \times 10^{-8}$ ) in meta-analyses and replication in multiple studies.<sup>22</sup> Much work remains to characterize exact variants in or near these susceptibility genes; however, the genes have been linked to the metabolism of A $\beta$  and synaptic function (*APOE*, *BIN1*, *CD33*, *CLU*, *CR1*, *PICALM*), the immune system and inflammation (*ABCA7*, *CD33*, *CLU*, *CR1*, *MS4A*), and lipid metabolism (*ABCA7*, *APOE*, *BIN1*, *CLU*, *PICALM*). These susceptibility genes, with the exception of *APOE*, all confer a relatively small risk for AD, with odds ratios of 0.85 to 1.2 (► **Table 2**).<sup>23,24</sup> The proportion of LOAD cases that could be prevented if these nine (GWAS-identified) genetic risk factors were eliminated, referred to as the cumulative population attributable risk, is estimated to be as high as 35%.<sup>25</sup> Studies are actively underway to identify additional disease-related associations in LOAD.

## Genetics of Frontotemporal Lobar Degeneration

Frontotemporal lobar degeneration (FTLD) is a term that describes the neuropathology underlying several different clinical syndromes, all characterized by progressive damage to the frontal and/or temporal lobes of the brain. As a result, behavior and language are progressively impaired in individuals affected with FTLD. Frontotemporal lobar degeneration

**Table 2** Established risk loci for late-onset Alzheimer's disease

Gene	Protein	Chromosome location	Effect size / Odds ratio (95% CI) <sup>a</sup>
<i>ABCA7</i>	ATP-binding cassette, subfamily A, member 7	19p13.3	1.23 (1.18–1.28)
<i>APOE</i>	Apolipoprotein E	19q13.32	$\epsilon$ 3 $\epsilon$ 4 genotype 3.2 (2.8–3.8) $\epsilon$ 4 $\epsilon$ 4 genotype 14.9 (10.8–20.6)
<i>BIN1</i>	Bridging integrator 1	2q14.3	1.17 (1.13–1.20)
<i>CD2AP</i>	CD2-associated protein	6p12.3	1.12 (1.08–1.16)
<i>CD33</i>	CD33 molecule	19q13.41	0.85 (0.86–0.92)
<i>CLU</i>	Clusterin	8p21.1	0.89 (0.86–0.91)
<i>CR1</i>	Complement component receptor 1	1q32.2	1.19 (1.09–1.30)
<i>MS4A4E</i> , <i>MS4A6A</i>	Membrane-spanning 4-domains, subfamily A, member 4E and 6A	11q12.2	0.90 (0.88–0.93)
<i>PICALM</i>	Phosphatidylinositol binding clathrin assembly protein	11q14.2	0.88 (0.86–0.91)

<sup>a</sup>Effect sizes calculated from AlzGene meta-analysis.<sup>22</sup>

typically presents at an earlier age than AD (~ 45–65 years of age) and represents the second most common cause of dementia in those under 65 years of age. Almost half of individuals with FTLN have other affected family members, and an autosomal dominant mode of transmission can be identified in ~ 10% of patients.<sup>26</sup>

Six unrelated genes with over 150 reported mutations have been implicated in FTLN (► **Table 3**; Alzheimer Disease and Frontotemporal Dementia Mutation database). Mutations in three genes (*C9ORF72*, *GRN*, *MAPT*) are the most common, with rarer causative mutations found in the remaining three genes (*CHMP2B*, *TARDBP*, *VCP*). Individuals with mutations in *C9ORF72*, *GRN*, or *MAPT* often present with the most common frontotemporal dementia clinical syndrome, the behavioral variant (bvFTD). Together, mutations in these three genes account for at least 17% of familial FTLN.<sup>27</sup> Although there are strong correlations between the mutated gene and the patient's neuropathology, there is typically not a clear association between the implicated gene and clinical phenotype.<sup>27</sup>

Microtubule-associated protein tau (*MAPT*), located on chromosome 17, is involved in microtubule assembly and maintenance, and has been implicated in FTLN, AD, and other neurologic diseases.<sup>28–30</sup> Over 40 mutations have been reported in the gene since its discovery in 1998, mostly in exons 9–13 (► **Fig. 2**). Mutations result in a change in the ratio of the three amino acid (3R) and four amino acid (4R) isoforms and are believed to increase the tendency of tau to form neurotoxic aggregates. Mutations in *MAPT* are found in ~ 9 to 21% of FTD patients.<sup>31</sup>

Some FTLN families demonstrated genetic linkage to chromosome 17, but surprisingly no mutations in *MAPT* could be found. It was later discovered that many of these families had mutations in progranulin (*GRN*), located only 6 Mb from *MAPT*.<sup>32,33</sup> Over 60 disease-producing mutations have been reported in *GRN*. Most result in a premature stop codon and the resulting mRNA is degraded through nonsense-mediated decay resulting in haplo insufficiency.<sup>34</sup> Of note, there is substantial clinical variability in patients carrying a *GRN* mutation. Mutations have been reported among individuals diagnosed clinically with language variants and bvFTD, AD, corticobasal degeneration, and mild cognitive impairment. The age of onset has varied widely, even within families.<sup>35</sup> *GRN* mutations are found in ~ 4 to 23% of all FTLN patients.<sup>31</sup>

Recently, expansions of a GGGGCC hexanucleotide repeat in the noncoding portion (first intron) of *C9orf72* on chromosome 9 have been associated with both FTLN and amyotrophic lateral sclerosis (ALS).<sup>36–39</sup> The repeat number, typically less than 25 units in normal individuals, is expanded to greater than 60 units in FTLN. The expanded number of repeats results in the loss of one alternatively spliced transcript. However, the function of this lost transcript is not yet known. Estimations for the percentage of familial ALS and familial FTLN cases in North American populations attributable to the *C9orf72* mutation range from 23.5 to 36.2% and 6.3 to 19.1%, respectively.<sup>39</sup> The *C9orf72* mutation appears to be more common among northern European populations.<sup>35</sup>

Mutations in the other three genes, chromatin modifying 2B (*CHMP2B*), valosin-containing protein 1 (*VCP-1*) and TAR-DNA-binding protein 43 encoding gene (*TARDBP*), are rare causes of FTD, found in only a few families each. The phenotype in each is quite different and may also be associated with non-FTD phenotypes. For example, some *VCP-1* mutations are associated with Paget's disease of the bone.<sup>35</sup>

There has only been one systematic FTLN GWAS, which reported *TMEM106B* on chromosome 7 as a potential susceptibility gene for FTLN cases with TAR-DNA-binding protein inclusions.<sup>40</sup> The identified SNPs were associated with increased *TMEM106B* expression, but the mechanism of upregulation and the development of FTLN has not been established.


## Genetic Counseling and Testing

Definitive diagnoses for AD and FTD can only be made at autopsy, but genetics may be used to increase diagnostic and prognostic accuracy. With the current limitations regarding disease-modifying therapies for neurodegenerative diseases and the complex ethical considerations involved in genetic testing, clinicians must carefully consider the appropriateness of genetic analyses for patients. Because both positive and negative findings have significant implications for the patient and family, thorough genetic counseling is advised before and after any genetic testing is performed. For genetic tests that are not commercially available, the tests may be available in the academic research setting. As more is learned about the genetics of AD and FTLN, commercial availability of genetic testing, and even direct to consumer testing, will

**Table 3** Mendelian genes causing frontotemporal lobar degeneration (FTLN)

Gene	Protein	Location	Mutation frequency in FTLN patients <sup>a</sup>	Types of mutations reported
<i>MAPT</i>	Microtubule-associated protein tau	17q21.1	9–21%	Missense, deletions
<i>GRN</i>	Progranulin	17q21.31	4–23%	Missense, deletions, insertions
<i>C9orf72</i>	Chromosome 9 open reading frame 72	9p21	18–30%	Hexanucleotide repeat expansion
<i>TARDBP</i>	TAR DNA binding protein	1p36.22	Rare	Missense
<i>VCP</i>	Valosin-containing protein	9p13.3	Rare	Missense
<i>CHMP2B</i>	Charged multivesicular body protein 2B	3p11.2	Rare	Missense

<sup>a</sup>Mutation frequencies calculated by Cohn-Hokke PE et al.<sup>31</sup>



**Fig. 2** Location of mutations within the *MAPT* protein product as generated from the Alzheimer Disease and Frontotemporal Dementia Mutation database.<sup>12</sup> Depicted is the chain of amino acids produced from the *MAPT* gene. Green indicates sites of reported nonpathogenic mutations, and red indicates sites of reported pathogenic mutations. Exon boundaries are marked by Ex\*, and microtubule-binding domains are shown in blue.

likely increase. As treatments are developed, testing options will likely expand further. Clinicians will need to be familiar with these options in an effort to counsel patients.

At present, routine DNA testing in AD is advisable only for EOAD, if the presenting affected individual is a young or middle-aged adult (onset < 60 years). Testing for mutations in PSEN 1, PSEN 2, and APP is currently commercially available. *APOE* genotyping is also available, and there are ongoing studies assessing the advantages and disadvantages of *APOE* genotyping. Most groups do not currently recommend the test for predictive risk assessment.<sup>41</sup>

With the heterogeneity of FTLD, the recommendations for genetic testing in symptomatic patients and their families are more complex. Considerations include the type of FTLD, the extent of family history, and the availability and findings of autopsy tissue from an affected family member. Genetic testing is available for *MAPT*, *GRN*, *VCP*, and *C9orf72* in the United States. A full algorithm for when genetic testing should be recommended has been previously reported.<sup>42</sup>

## Conclusion and Outlook

Although much has been discovered about the genetics of dementia, the genetic contribution to the vast majority of sporadic and some Mendelian cases of dementia has not yet been elucidated. Modern genetic technologies have helped identify causative and risk loci, but much work remains to characterize the biological mechanisms of these genes and

the disease-producing mutations. As additional genetic loci are recognized and characterized, correlations between genotypes and phenotypes will become better understood. Phenotypes will not only include presenting symptoms, but also biomarkers such as structural and functional imaging and composition of the cerebrospinal fluid. Methodologies for screening, diagnosis, and prognosis will improve as additional genes and mutations are identified and correlated with increasingly specific phenotypes. Most importantly, advancing knowledge of underlying genetic factors in neurodegenerative dementias will inform the pursuit of preventative and disease-modifying therapies.

## Acknowledgments

This publication was made possible by Grant Number TL1 TR000162 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award, as well as the National Cell Repository for Alzheimer's Disease, which receives government support under the cooperative agreement grant U24 AG21886.

## References

- Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 1991;349(6311):704–706

- 2 Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. *Science* 1990;248(4959):1124–1126
- 3 Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. *Biochem Biophys Res Commun* 1984;122(3):1131–1135
- 4 Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. *Ann Med* 2008;40(8):562–583
- 5 Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* 1995;375(6534):754–760
- 6 Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 1995;269(5226):973–977
- 7 Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. *Nature* 1995;376(6543):775–778
- 8 Finckh U, Müller-Thomsen T, Mann U, et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. *Am J Hum Genet* 2000;66(1):110–117
- 9 Lleó A, Blesa R, Queralt R, et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. *Arch Neurol* 2002;59(11):1759–1763
- 10 Piscopo P, Marcon G, Piras MR, et al. A novel PSEN2 mutation associated with a peculiar phenotype. *Neurology* 2008;70(17):1549–1554
- 11 De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. *Nature* 1998;391(6665):387–390
- 12 Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. *Hum Mutat* 2012;33(9):1340–1344
- 13 Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. *Biochemistry* 1993;32(18):4693–4697
- 14 Bird TD. Alzheimer disease overview. *GeneReviews*. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1161/>. Accessed October 1, 2013
- 15 Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry* 2006;63(2):168–174
- 16 Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. *JAMA Neurol* 2013;70(4):440–444
- 17 Farrer LA, Cupples LA, Haines JL, et al; APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. *JAMA* 1997;278(16):1349–1356
- 18 Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. *Ann Neurol* 1995;37(2):254–259
- 19 Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. *Ann Neurol* 1993;34(5):752–754
- 20 Ueki A, Kawano M, Namba Y, Kawakami M, Ikeda K. A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease. *Neurosci Lett* 1993;163(2):166–168
- 21 Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Genet* 1994;7(2):180–184
- 22 Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. *Lancet Neurol* 2013;12(1):92–104
- 23 Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. *Nat Rev Neurosci* 2008;9(10):768–778
- 24 Paulson HL, Igo I. Genetics of dementia. *Semin Neurol* 2011;31(5):449–460
- 25 Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* 2011;43(5):436–441
- 26 Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. *Neurology* 2009;73(18):1451–1456
- 27 Sieben A, Van Langenhove T, Engelborghs S, et al. The genetics and neuropathology of frontotemporal lobar degeneration. *Acta Neuropathol* 2012;124(3):353–372
- 28 Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 1998;393(6686):702–705
- 29 Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. *Ann Neurol* 1998;43(6):815–825
- 30 Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. *Proc Natl Acad Sci U S A* 1998;95(13):7737–7741
- 31 Cohn-Hokke PE, Elting MW, Pijnenburg YA, van Swieten JC. Genetics of dementia: update and guidelines for the clinician. *Am J Med Genet B Neuropsychiatr Genet* 2012;159B(6):628–643
- 32 Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 2006;442(7105):916–919
- 33 Cruts M, Gijssels I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* 2006;442(7105):920–924
- 34 Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. *Hum Mol Genet* 2006;15(20):2988–3001
- 35 Galimberti D, Scarpini E. Genetics of frontotemporal lobar degeneration. *Front Neurol* 2012;3:52
- 36 DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. *Neuron* 2011;72(2):245–256
- 37 Gijssels I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. *Lancet Neurol* 2012;11(1):54–65
- 38 Renton AE, Majounie E, Waite A, et al; ITALSGEN Consortium. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 2011;72(2):257–268
- 39 Cruts M, Gijssels I, Van Langenhove T, van der Zee J, Van Broeckhoven C. Current insights into the C9orf72 repeat expansion diseases of the FTD/ALS spectrum. *Trends Neurosci* 2013;36(8):450–459
- 40 Van Deerlin VM, Sleiman PMA, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nat Genet* 2010;42(3):234–239
- 41 Goldman JS, Hahn SE, Catania JW, et al; American College of Medical Genetics and the National Society of Genetic Counselors. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. *Genet Med* 2011;13(6):597–605
- 42 Goldman JS, Rademakers R, Huey ED, et al. An algorithm for genetic testing of frontotemporal lobar degeneration. *Neurology* 2011;76(5):475–483

# Author Query Form (SIN/00885)

**Special Instructions: Author please write responses to queries directly on proofs and then return back.**

Q1: AU: Please provide degree.

Q2: AU: Is "interrogate" the right word here?



THIEME